Quick search:
Result Content Outlet Published Research
Result Content Outlet Published Research
1 Chari Discusses Prominent Trials For Newly Diagnosed Multiple Myeloma Targeted Oncology 6 months ago
2 Subcutaneous Daratumumab Plus Kd Is a “Gamechanger” for Patients With Multiple Myeloma OncLive 4 months ago
3 Talquetamab/Daratumumab Shows Promise in Heavily Pretreated Myeloma, Warranting Further Investigation OncLive 3 months ago
4 New Blood Tests Reduce Need for Bone Marrow Biopsy in Multiple Myeloma Targeted Oncology 2 months ago
5 Mount Sinai Announces Landmark Gift from James S. and Merryl H. Tisch to Transform Cancer Care in New York Mount Sinai 9 months ago
6 Experts discuss management of cancer therapies in the era of COVID-19 Healio 6 months ago
7 Darzalex Faspro Combo Therapy for Myeloma Patients Approved by FDA Myeloma Research News 5 months ago
8 TRIMM-2: favourable results of talquetamab plus daratumumab for multiple myeloma Physician's Weekly 5 months ago
9 FDA Approves Time-Saving Combo for R/r Multiple Myeloma Medscape 6 months ago
10 Priorities for Relapsed Multiple Myeloma Treatments | PPA Dove Medical Press 3 months ago
11 ASH 2020 Data: DKd Versus DVd Implications Managed Markets Network 1 year ago
12 Combination Regimens Show Different Levels of Efficacy for Patients With Myeloma Ineligible for Transplant Targeted Oncology 1 year ago
13 Implications of the IKEMA Interim Analysis Managed Markets Network 1 year ago
14 Ash 2020 – multiple myeloma goes beyond BCMA Vantage 1 year ago
15 R/R Multiple Myeloma Rationale for Decreased Response Managed Markets Network 1 year ago
16 Colin Powell's COVID-19 Death Followed Cancer Diagnosis, Treatment 7 months ago
17 ASH 2020: GPRC5D Is a New Target of Interest for Multiple Myeloma DocWire News 1 year ago
18 Talquetamab Shows Strong Safety and Efficacy Profile When Treating Patients with Heavily Pretreated Myeloma Cancer Network 1 year ago
19 Case Review: Standard-Risk Multiple Myeloma Targeted Oncology 3 years ago
20 Novel Triplets Shed New Light on Sequencing in Relapsed/Refractory Myeloma OncLive 1 year ago
21 Treating Biochemical Relapses in Multiple Myeloma Managed Markets Network 1 year ago
22 The Future of R/R Multiple Myeloma Management Managed Markets Network 1 year ago
23 Janssen Presents First Data from the Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma PR Newswire 1 year ago
24 Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio PR Newswire 2 years ago
25 Impact of the Phase 3 APOLLO Trial Recent Findings Managed Markets Network 1 year ago
26 Subcutaneous Daratumumab Appears Primed to Transform Myeloma Care OncLive 2 years ago
27 Approved Combinations and Novel Agents Expand Therapy Options Across Multiple Myeloma Settings Targeted Oncology 3 years ago